RARA CRAFT DATABASE for FDA Medical Devices
510(k)K230599

FDA DEVICE FACTS

TargetCool™

Recensmedical, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 22, 2023PRODUCT CODEGEH

Indications for use

/ Intended Use TargetCool™ are intended for the surgical destruction of target tissue by applying cryogenic gases at extreme low temperatures

- Molluscum Contagiosum

- Skin Tags

- Actinic Keratosis

- Lentigo

- Verruca Plana

- Verruca Vulgaris

- Verruca Lesions

- Genital Lesions

- Seborrheic Keratosis The CryoVIVE are intended for the surgical destruction of target tissue by applying cryogenic gases at extreme low temperatures

- Molluscum Contagiosum

- Skin Tags

- Actinic Keratosis

- Lentigo

- Verruca Plana

- Verruca Vulgaris

- Verruca Lesions

- Genital Lesions

- Seborrheic Keratosis Same Component Main system, Control button, LCD, Cooling nozzle, Freezing nozzle, Cooling guard, filter, CO2 cartridge and Boosting accessories (Boosting Nozzle, a Boosting guard, and a Main system, Control button, LCD, Nozzle (Cooling and Freezing), Guide tip, filter, CO2 cartridge Same Boosting Container). Mechanism of Action Cryogen, CO2 is delivered to the treatment site to effect cellular destruction Cryogen, CO2 is delivered to the treatment site to effect cellular destruction Same Temperature CO2 (-79°C) CO2 (-79°C) Same Gas dispensing rate 0.578 g/sec 0.578 g/sec Same Gas Volume 65g cartridge 65g cartridge Same Tissue damage Cell necrosis occurs only inside the ice ball Cell necrosis occurs only inside the ice ball Same

Cryoablation is the fundamental technological principle for the freezing mode of the subject device, TargetCool™, and the predicate devices (CryoVIVE). The Freezing mode of TargetCool™ is equivalent in intended use, principles of operation, and performance temperature to TargetCool™ (K221234) and raises no new issues of safety or effectiveness. The only difference is that the freezing nozzle's length is shortened and the guard is not inserted during the procedure in the freezing mode. Because of this the device can be placed closer to the lesion, so that it can be applied to smaller lesion sizes. However, these differences do not significantly affect safety and/or effectiveness.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026